Neumora Therapeutics (NMRA) Accounts Payables (2022 - 2026)

Neumora Therapeutics' Accounts Payables history runs 5 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• In Q1 2026, Accounts Payables rose 380.7% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $5.1 million (up 380.7% YoY), while the FY2025 annual figure was $3.4 million, up 2.18% from the prior year.
• Accounts Payables for Q1 2026 stood at $5.1 million, up from $3.4 million in the prior quarter.
• The five-year high for Accounts Payables was $7.1 million in Q4 2022, with the low at $337000.0 in Q4 2023.
• The 5-year median for Accounts Payables is $1.9 million (2023), against an average of $2.7 million.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables slumped 95.28% in 2023, then surged 881.31% in 2024.
• Neumora Therapeutics' Accounts Payables stood at $7.1 million in 2022, then plunged by 95.28% to $337000.0 in 2023, then soared by 881.31% to $3.3 million in 2024, then advanced by 2.18% to $3.4 million in 2025, then jumped by 49.66% to $5.1 million in 2026.
• Business Quant data shows NMRA's Accounts Payables at $5.1 million in Q1 2026, $3.4 million in Q4 2025, and $549000.0 in Q3 2025.